The Anti-Osteoporotic Drug Preferences of Physiatrists: A Multicenter Descriptive Study
Aim: The purpose of this multicenter descriptive study is to determine the preferences of physiatrists in our country for anti-osteoporotic drugs in patients with primary and secondary osteoporosis. Materials and Methods: This study was carried out in 10 provinces of Turkey. The diagnosis of osteo...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2012-08-01
|
| Series: | Türk Osteoporoz Dergisi |
| Subjects: | |
| Online Access: | http://www.turkosteoporozdergisi.org/article_4300/The-Anti-osteoporotic-Drug-Preferences-Of-Physiatrists-A-Multicenter-Descriptive-Study |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim: The purpose of this multicenter descriptive study is to determine the preferences of physiatrists in our country for anti-osteoporotic drugs
in patients with primary and secondary osteoporosis.
Materials and Methods: This study was carried out in 10 provinces of Turkey. The diagnosis of osteoporosis was based on World Health
Organization criteria using dual-energy x-ray absorptiometry. Patients with a spine and/or hip T-score ≤-2.5 were considered as osteoporotic. 714
patients over 18 years old with primary or secondary osteoporosis were included in the study. In addition to socio-demographic characteristics
and chronic use of medications and/or additional systemic diseases that cause secondary osteoporosis were questioned and antiosteoporotic
drugs that are recommended by their physicians were recorded.Results: The physicians’ preferred vitamin D and calcium as the prior treatment both in primary and secondary osteoporosis. The most commonly
used anti-osteoporotic agent was alendronate from the biphosphonate group. It was followed by ibandronate, risedronate, strontium ranelate,
calcitonin, zoledronate, raloxifene, parathyroid hormone (PTH) and hormone replacement therapy (HRT) in the primary osteoporosis and
risedronate, ibandronate, calcitonin, strontium ranelate, zoledronate, PTH, HRT and raloxifene in the secondary osteoporosis, respectively.
Conclusion: The physician should choose the most suitable treatment for the patient based on fracture risk, medical history, previous
treatments for osteoporosis, concomitant diseases, treatment-induced risks and benefits, and the relation between financial cost and potential
benefit. (Turkish Journal of Osteoporosis 2012;18: 42-6) |
|---|---|
| ISSN: | 2147-2653 |